Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
Reduction of Alkenes: Asymmetric Catalytic Hydrogenation02:17

Reduction of Alkenes: Asymmetric Catalytic Hydrogenation

Catalytic hydrogenation of alkenes is a transition-metal catalyzed reduction of the double bond using molecular hydrogen to give alkanes. The mode of hydrogen addition follows syn stereochemistry.
The metal catalyst used can be either heterogeneous or homogeneous. When hydrogenation of an alkene generates a chiral center, a pair of enantiomeric products is expected to form. However, an enantiomeric excess of one of the products can be facilitated using an enantioselective reaction or an...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chiral Pyrazolinylidene Complexes for Asymmetric Catalysis.

Chemistry (Weinheim an der Bergstrasse, Germany)·2026
Same author

Inhibition of acid sphingomyelinase links sphingolipid remodeling to necroptotic cell death.

RSC chemical biology·2026
Same author

Imidazol-2-ylidene-Based NCCN Ligands for Chiral-at-Iron Catalysis.

Organometallics·2026
Same author

Asymmetric Iron-Catalyzed Vicinal C(sp<sup>3</sup>)─H Diamination of Carboxylic Acids.

Angewandte Chemie (International ed. in English)·2026
Same author

Inhibition of Acid Sphingomyelinase Links Sphingolipid Remodeling to Necroptotic Cell Death.

bioRxiv : the preprint server for biology·2026
Same author

ER-localized ceramide accumulation contributes to replicative senescence.

Cell chemical biology·2026

Related Experiment Video

Updated: Jun 17, 2026

The Synthesis, Characterization and Reactivity of a Series of Ruthenium N-triphosPh Complexes
10:51

The Synthesis, Characterization and Reactivity of a Series of Ruthenium N-triphosPh Complexes

Published on: April 10, 2015

Inert ruthenium half-sandwich complexes with anticancer activity.

Eric Meggers1, G Ekin Atilla-Gokcumen, Katharina Gründler

  • 1Department of Chemistry, University of Pennsylvania, 231 S. 34th Street, Philadelphia, PA 19104, USA. meggers@chemie.uni-marburg.de

Dalton Transactions (Cambridge, England : 2003)
|December 22, 2009
PubMed
Summary

This study reveals that a novel ruthenium complex, NP309, exhibits anticancer properties by inhibiting glycogen synthase kinase 3 (GSK-3) and inducing apoptosis in cancer cells, without interacting with DNA.

More Related Videos

Synthesis and Evaluation of a Ruthenium-based Mitochondrial Calcium Uptake Inhibitor
07:12

Synthesis and Evaluation of a Ruthenium-based Mitochondrial Calcium Uptake Inhibitor

Published on: October 26, 2017

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
07:20

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Published on: May 28, 2014

Related Experiment Videos

Last Updated: Jun 17, 2026

The Synthesis, Characterization and Reactivity of a Series of Ruthenium N-triphosPh Complexes
10:51

The Synthesis, Characterization and Reactivity of a Series of Ruthenium N-triphosPh Complexes

Published on: April 10, 2015

Synthesis and Evaluation of a Ruthenium-based Mitochondrial Calcium Uptake Inhibitor
07:12

Synthesis and Evaluation of a Ruthenium-based Mitochondrial Calcium Uptake Inhibitor

Published on: October 26, 2017

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
07:20

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Published on: May 28, 2014

Area of Science:

  • Medicinal Chemistry
  • Biochemistry
  • Cancer Biology

Background:

  • Investigating novel anticancer agents is crucial for developing new cancer therapies.
  • Metal complexes offer unique scaffolds for drug design.
  • Understanding drug-target interactions and mechanisms of action is key to optimizing efficacy.

Purpose of the Study:

  • To explore the anticancer properties of a novel inert half-sandwich metal complex.
  • To elucidate the mechanism of action of the ruthenium complex NP309.
  • To assess the potential of NP309 in overcoming drug resistance.

Main Methods:

  • UV melting experiments with duplex DNA and (1)H-NMR experiments with 9-ethylguanine to assess DNA interaction.
  • Kinase inhibition assays to evaluate the effect of structural modifications on enzyme activity.
  • Cytotoxicity assays (IC50) and apoptosis induction studies in cancer cell lines (BJAB).
  • Mitochondrial membrane potential assessment, caspase-9 processing, and Bcl-2 expression analysis.

Main Results:

  • The ruthenium complex DW12 does not interact with DNA.
  • Methylation of DW12 (DW12-Me) abolished anticancer activity, indicating kinase inhibition is essential.
  • NP309 showed improved IC(50) for glycogen synthase kinase 3 (GSK-3) and enhanced cytotoxicity.
  • NP309 induced apoptosis in BJAB cells via mitochondrial pathway and caspase-9 activation, partly dependent on Bcl-2.
  • NP309 demonstrated efficacy against drug-resistant human B-cell precursor lines.

Conclusions:

  • Anticancer activity of the investigated complexes correlates with GSK-3 inhibition.
  • NP309 induces apoptosis through a well-defined mitochondrial pathway.
  • NP309 shows promise as a therapeutic agent, particularly against resistant B-cell malignancies.